Haematologic malignancies account for approximately 7% of all cancer diagnoses¹. They are severe, often life-threatening diseases that require rapid and accurate diagnosis to ensure timely clinical management.

This group of diseases comprises more than 100 distinct entities², many of which present with similar or overlapping clinical features, making diagnosis a complex, multi-step process that relies on close collaboration between the haematology, flow cytometry, molecular diagnostics, and haemostasis laboratories. An integrated diagnostic approach is therefore essential – up to 15% of blood cancers may be misdiagnosed when patients are not evaluated in specialised centres³.

Sysmex’s high-quality diagnostic solutions support laboratories and clinicians throughout the entire haemato-oncology patient journey, enabling healthcare professionals to drive better outcomes and deliver excellence in haemato-oncology.

‘The accuracy of the diagnosis only comes from integrating those results (…) and the clinical background of that patient. (…). It is crucial to select the right method at the right point, and so working with a team of people that are all working towards that diagnostic accuracy is key.’

Dr Polly Talley PhD FRCPath, Consultant Clinical Scientist, Haematological Malignancy Diagnostic Service (HMDS), Leeds, UK

Delivering insight across the care continuum

Interdisciplinary diagnostics | Four disciplines. One coherent outcome.

Sysmex supports the disciplines that matter ‒ so the picture becomes clear.

Haematology

From advanced cell counting to digital cell morphology

Flow cytometry

Immunophenotyping with insights from integrated data

Genetic testing

Molecular characterisation with cytogenetic and molecular genetic testing

Haemostasis

Concurrent coagulation testing with specific assays

From advanced blood cell counting to digital blood and bone marrow cell morphology analysis

It all starts with a complete blood count (CBC), but there is more to it than meets the eye! Go beyond basic counts with advanced blood parameters that offer a deeper insight into the physiology of patients.

Be alerted to incidental findings of leukaemia through best-in-class proprietary algorithms for the detection of immature precursor cells with every DIFF measurement.
Identify immature cells circulating in the periphery
- Nucleated red blood cells (NRBC) for haematopoietic stress
- Immature granulocytes (IG) for guiding further tests
Assess the immune response against infections
- Evaluate the activation of neutrophils and lymphocytes
Assess iron availability with the reticulocyte haemoglobin equivalent (RET-He)
- RET-He can support anaemia diagnostics in leukaemic patients
Get precise counts in cytopenias
- Reliable WBC values in severe leucocytopenic samples
- Accurate platelet count as low as the transfusion threshold

Combine with AI-powered digital morphology for more precise haematopathology insights. From peripheral blood and bone marrow samples.

Go back to top

Find more information here

Anaemia in patients with haematologic malignancies

Be confident in appropriate anaemia diagnosis and therapy

Learn more

Incidential finding of haematologic malignancies

Recognize the early signs of leukaemia already from standard blood cell count analysis

Learn more

Observe early signs of successful stem cell engraftment

Patient management in haematopoietic stem cell transplantation

Learn more

Flow cytometry

Comprehensive insights into haematologic malignancies: leukaemia & lymphoma immunophenotyping

Accurate diagnosis and monitoring of haematologic malignancies require a comprehensive and precise approach. Flow cytometric immunophenotyping plays a critical role in detecting aberrant cell populations, supporting clinicians in making informed treatment decisions. With a wide range of Sysmex CyFlow™ CE-IVD antibody reagents, laboratories can perform immunophenotyping analysis to support the diagnosis and classification of haematological diseases.

Seamless data integration delivers accurate, reproducible, and clinically relevant insights into flow cytometry and haematology results

In haemato-oncology, seamless data integration is key to delivering timely, accurate, and clinically relevant insights. CyFlow WA connects haematology and flow cytometry data streams into a unified workflow, enhancing traceability, standardisation, and result validation. Through automated data management and bidirectional LIS connectivity, it supports efficient and consistent laboratory workflows, enabling healthcare professionals to review and validate results within a comprehensive data environment.

Go back to top

Find more information here

CyFlow WA

Our new work area manager for a smartly linked clinical flow cytometry lab.

Smartly linked

Identifying a typical CLL by means of two complementary technologies

This case study explains how the same lymphocytes react in two different complementary methods: fluorescence flow cytometry in the WPC channel of the XN-Series haematology analyser and multicolour immunophenotyping using the XF-1600 analyser.

Download

Flow cytometry antibody reagents

High-quality flow cytometry antibody reagents for clinical diagnostic and clinical research applications.

Explore our portfolio

Genetic testing

Cytogenetic and molecular genetic testing solutions for clinical management and research

For patient stratification and treatment decisions, it is crucial to characterise the disease-specific genetic alterations. Today, advanced molecular genetic tools are employed for the precise determination of the blood cancer type, both in routine and clinical research settings. Fluorescence in situ hybridisation (FISH) enables the detection of chromosomal abnormalities.

CytoCell^® high-quality, reliable and easy-to-use DNA probes for FISH for haematological malignancies supporting patient diagnostic and clinical management. Whether IVDR-certified, tri-colour, FAST-protocol or customised FISH, there is a right CytoCell probe to meet your requirements.

Further your clinical research with our NGS solutions

Next-generation sequencing (NGS) provides detailed insights into minute genetic mutations and allows monitoring of disease evolution.

SureSeq™ NGS panels, library preparation kits and software supporting clinical research on genetic prognosis stratification and measurable residual disease (MRD). Designed to detect even low-frequency variants with confidence in key targets such as NPM1, FLT3-ITD, KMT2A-PTDs, JAK2, BCL2 and BTK.

SureSeq™: For Research Use Only. Not for use in diagnostic procedures.
CytoCell^®: Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representatives for availability.

Go back to top

Find more information here

CytoCell (FISH)

High quality, reliable and easy-to-use DNA probes for fluorescence in situ hybridisation (FISH)

Learn more

SureSeq

Next-generation sequencing – panels, library preparation kits and software for cytogenetics and blood cancer research

Learn more

Webinar

Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study – AMP 2025 corporate workshop

Watch the webinar

Haemostasis

Comprehensive coagulation testing to manage cancer-associated thrombotic risk and comorbidities

Cancer is associated with a substantially increased risk of venous thromboembolism (VTE). VTE is the second leading cause of death in patients with cancer, after cancer progression itself. ^{4 5 6}

Approximately one in five patients presenting with VTE has an underlying malignancy, highlighting the close relationship between cancer and thrombosis. ^{4 6}

In addition to cancer type, numerous contributors to thrombotic risk have been identified, including patient-related factors, tumour characteristics, and anticancer treatments (Fig. 1). ^{4 5 6}

Fig. 1: Risk factors and predictors for VTE in cancer patients (adapted from [5] with updates) CAR-T cell = Chimeric antigen receptors-T cell, TAT = Thrombin-antithrombin complex, ETP = Endogenous thrombin potential, VEGF = Vascular endothelial growth factor, MPV = Mean platelet volume.

Cancer type and D-dimer level:

Elevated D-dimer levels are associated with an increased risk of VTE in patients with cancer and may support thrombotic risk assessment in selected clinical settings. ^{4 6}
INNOVANCE^® D-Dimer has demonstrated a diagnostic sensitivity of > 98% for the exclusion of VTE (DVT and PE) according to the Instructions for Use.⁸
Results may help identify patients who could benefit from closer surveillance and appropriate preventive strategies, in conjunction with current clinical guidelines. ^{6 7}
Support anticoagulant therapy management, where clinically indicated, using the Revohem^® Anti-Xa LRT assay.

Go back to top

Find more information here

Webinar

Venous thromboembolism and cancer: learn about the potential bleeding and thrombosis risks associated with CAR-T cell therapy, a revolutionary treatment for certain types of cancer.

Watch the webinar

CN-Series

Power up your haemostasis lab

Find out more

Haemostasis

Sysmex empowers haemostasis laboratories with a connected ecosystem of coagulation analysers, haemostasis reagents, laboratory automation and expert support.

Whatever drives you, we can empower you

Watch our video: A story of leukemia

Smartly linked APL diagnostics

A clinical challenge: acute promyelocytic leukaemia (APL) is a medical emergency, but it is rare, and symptoms are non-specific.

APL is a distinct form of acute myeloid leukaemia strongly associated with dysregulated coagulation, very frequently resulting in disseminated intravascular coagulopathy (DIC), which can cause life-threatening bleeding and thrombotic complications, especially in the early stages of the disease.

APL is highly curable if recognised early and promptly treated.
Delay results in the rapid evolution of bleeding abnormalities with a high mortality rate.
Improved linkage of diagnostic information from haemostasis, haematology, and clinical flow cytometry allows for earlier recognition of suspected APL, followed by genetic confirmation, which is essential for the timely design of a targeted treatment plan.

Learn more about acute promyelocytic leukaemia

References

[1] Siu, Lillian L. (2026): The Global State of Blood Cancers: An Ongoing Challenge. Blood Cancer Discovery 7.1: 25–30.

[2] Alaggio R, Amador C, Anagnostopoulos I et al. (2022): The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36, 1720–1748.

[3] Ireland R. (2011): Haematological malignancies: the rationale for integrated haematopathology services, key elements of organization and wider contribution to patient care. Histopathology, 58: 145–154.

[4] Ay C, Pabinger I, Cohen AT. (2017): Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost. 2017 Jan 26;117(2):219-230. doi: 10.1160/TH16-08-0615 (open access)

[5] Faille D, Bourrienne MC, de Raucourt E, de Chaisemartin L, Granger V, Lacroix R, Panicot-Dubois L, Hammel P, Levy P, Ruszniewski P, Ajzenberg N, Rebours V. (2018): Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget. 2018 May 29;9(41):26453-26465. (open access)

[6] Falanga A, Ay C, Di Nisio M, et al. (2023): Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol.; 34(5):452–467.

[7] Streiff MB, Holmstrom B, Angelini D, et al. (2024): Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.; 22(7):483–520.

[8] Instructions for Use (2026): INNOVANCE® D-Dimer Reagent